Work

P3.18.37 A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC With PD-L1 TPS =50%

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.1052

Authors: T-E. Ciuleanu, R.A. Ramírez Fallas, T. Göksel, S.J. Kim, G. Song, S. Zhang, B. Halmos

Institutions: Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta, Ege University, Merck & Co., Inc., Rahway, NJ, USA (United States), Albert Einstein College of Medicine, Montefiore Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415519098

FWCI:

Cites:

Cited by:

Related to: